Blood advances
Decitabine-cedazuridine in patients with MDS and TP53 mutations.
Samuel Urrutia, Koji Sasaki, Alex Bataller, Hagop M Kantarjian, Guillermo Montalban-Bravo, James McCloskey, Elizabeth A Griffiths, Karen W L Yee, Amer M Zeidan, Michael R Savona, Aram Oganesian, Yuri Sano, Harold Neal Keer, Guillermo Garcia-Manero
Published: 202510.1182/bloodadvances.2025017745
Abstract
Patients with myelodysplastic syndromes (MDS) harboring TP53 mutations have poor outcomes. The objective of this study is to evaluate patients with TP53 mutations treated in the phase 2/3 studies of decitabine-cedazuridine (DEC-C) in MDS. We divided…
Preview only. Read the full abstract at the source